Samsung Biologics has entered a strategic manufacturing partnership with Eli Lilly to accelerate the global supply for Lilly’s Covid-19 antibody therapies with the ultimate goal of making antibody treatments more globally accessible for patients.   Lilly’s success in developing neutralizing antibodies against Covid-19, augmented with Samsung Biologics’ manufacturing scale, signals a major move forward in delivering important treatments to patients suffering from the deadly pandemic.     “Neutral...